The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tasisulam-sodium in combination with liposomal doxorubicin in patients with ovarian cancer.
D. Scott McMeekin
Research Funding - Lilly
Lee S. Rosen
No relevant relationships to disclose
Alberto Bessudo
Research Funding - Lilly
Datchen Fritz Tai
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Robert L. Ilaria
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jian Chen
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
P. Kellie Turner
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Sandia Krueger
Employment or Leadership Position - Lilly
Michael S. Gordon
Research Funding - Lilly